Pull to refresh
Logo
FDA approves WELTRUZA, first once-monthly subcutaneous olanzapine for schizophrenia

FDA approves WELTRUZA, first once-monthly subcutaneous olanzapine for schizophrenia

New Capabilities

The Teva and Medincell shot removes the post-injection monitoring that shaped use of the prior injectable olanzapine

Today: FDA approves WELTRUZA

Overview

Updated 1 hour ago

Teva's WELTRUZA is the first once-monthly subcutaneous injection of olanzapine for schizophrenia. Patients skip loading doses, oral supplementation, and the post-injection clinic stay that defined the previous injectable form of this drug.

The FDA based its approval on Phase 3 SOLARIS data showing symptom improvement across three strengths: 318 mg, 425 mg, and 531 mg. Launch in U.S. pharmacies comes within weeks, and European review is already underway.

Why it matters

WELTRUZA is the first olanzapine injection that doesn't require post-dose clinic observation, removing a burden that pushed patients and clinicians toward other antipsychotics.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

3
Dose strengths: 318, 425, 531 mg
Strengths correspond to 10, 15, and 20 mg daily oral olanzapine.
$112M
Milestone payments Medincell could receive
Includes a $4M payment upon U.S. approval plus up to $105M in sales-based commercial milestones.
5%
WELTRUZA discontinuation rate from adverse events
Placebo discontinuation rate in the SOLARIS trial was 4%.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

April 2023 October 2026

3 events Latest: Today
  1. FDA approves WELTRUZA

    Today Regulatory

    FDA approves WELTRUZA, first once-monthly subcutaneous olanzapine injection for schizophrenia.

  2. EMA accepts olanzapine LAI application

    Regulatory

    European Medicines Agency accepts Teva's marketing application for TEV-'749, the olanzapine long-acting injectable.

  3. FDA approves Uzedy

    Regulatory

    FDA clears Uzedy (risperidone), first drug on Medincell's SteadyTeq long-acting platform.

Scenarios

1

WELTRUZA reaches U.S. patients within weeks

Likely Resolves by End of 2026

Discussed by: Teva Pharmaceuticals, Medincell

Teva says the drug will be available in the coming weeks across three strengths. For this to resolve YES, Teva must confirm commercial availability or the product must appear in pharmacy channels. Launch timing is the clearest near-term checkpoint.

2

EMA grants European approval for TEV-'749

Likely Resolves by Q2 2027

Discussed by: European Medicines Agency review process

EMA accepted the marketing application for TEV-'749 in May 2026, supported by the same SOLARIS study. A standard review typically concludes within about a year of acceptance. The U.S. approval strengthens the case but doesn't guarantee the European decision.

3

Post-marketing data answers the PDSS question

Uncertain Resolves by End of 2027

Discussed by: PharmTech, pharmacovigilance community

WELTRUZA's label still carries the post-injection delirium/sedation syndrome language from the intramuscular product, noting it's unknown whether PDSS can occur with subcutaneous delivery. The key question: does the copolymer's controlled release prevent the rapid drug spikes behind PDSS? The first year of real-world use will show.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

Pre-2026

The intramuscular olanzapine era

The prior long-acting olanzapine was given intramuscularly and linked to post-injection delirium/sedation syndrome, where too much drug enters the bloodstream too quickly. Patients needed extended observation after each dose.

Then

Clinics built observation time into every injection visit, making injectable olanzapine logistically heavy.

Now

The monitoring burden shaped how readily clinicians prescribed injectable olanzapine, steering many toward alternative antipsychotics.

Why this matters now

WELTRUZA removes the monitoring requirement. Its label still describes the PDSS risk from the intramuscular product, and says it's unknown whether the syndrome can occur with the subcutaneous formulation.

April 2023

Uzedy validates the SteadyTeq platform (2023)

FDA approved Uzedy, a risperidone long-acting injectable using Medincell's copolymer technology. It was the first product cleared on the SteadyTeq platform.

Then

The approval showed the polymer delivery system could safely release an antipsychotic over a month.

Now

WELTRUZA is the second approval on the same platform, suggesting polymer depot technology can extend to other molecules with established efficacy.

Why this matters now

Two approvals on one delivery system may shorten development timelines for future drugs, since polymer supply, analytical methods, and sterile manufacturing experience already exist.

Sources

(10)